Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aptinyx Inc (APTX)

Aptinyx Inc (APTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,501
  • Shares Outstanding, K 67,720
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,850 K
  • EBIT $ -64 M
  • EBITDA $ -63 M
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.36
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.98
  • Most Recent Earnings $-0.31 on 05/18/23
  • Next Earnings Date 01/02/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +78.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0090 +966.67%
on 12/19/23
0.0960 unch
on 12/29/23
+0.0325 (+51.18%)
since 11/29/23
3-Month
0.0090 +966.67%
on 12/19/23
0.0960 unch
on 12/29/23
+0.0286 (+42.43%)
since 09/29/23
52-Week
0.0090 +966.67%
on 12/19/23
0.7200 -86.67%
on 02/13/23
-0.2041 (-68.01%)
since 12/29/22

Most Recent Stories

More News
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives

Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022.

APTX : 0.0960 (+3.11%)
Stocks Mixed Before The Open As Fed Fears Persist, Target Earnings On Tap

March S&P 500 futures (ESH23) are trending up +0.07% this morning after three major U.S. benchmark indices ended the regular session higher as investors digested an early round of U.S. economic data and...

ESH23 : 3,957.05s (-0.09%)
TSLA : 389.79 (+0.15%)
SGEN : 228.74 (-0.07%)
UNP : 233.54 (+0.56%)
ZM : 85.58 (-0.74%)
WDAY : 279.91 (+5.06%)
TGT : 135.29 (+2.19%)
MNST : 53.21 (+1.80%)
HPQ : 36.45 (+0.69%)
RIVN : 14.45 (+11.15%)
NCLH : 25.96 (-6.11%)
BAYN.D.DX : 20.240 (+1.12%)
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase...

APTX : 0.0960 (+3.11%)
Aptinyx to Present at the SVB Securities Global Biopharma Conference

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D.,...

APTX : 0.0960 (+3.11%)
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience

Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster presentations...

APTX : 0.0960 (+3.11%)
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for...

APTX : 0.0960 (+3.11%)
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the finalization of a $5.6 million...

APTX : 0.0960 (+3.11%)
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will...

APTX : 0.0960 (+3.11%)
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment...

APTX : 0.0960 (+3.11%)
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase...

APTX : 0.0960 (+3.11%)

Business Summary

Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in...

See More

Key Turning Points

3rd Resistance Point 0.1040
2nd Resistance Point 0.1000
1st Resistance Point 0.0980
Last Price 0.0960
1st Support Level 0.0920
2nd Support Level 0.0880
3rd Support Level 0.0860

See More

52-Week High 0.7200
Fibonacci 61.8% 0.4484
Fibonacci 50% 0.3645
Fibonacci 38.2% 0.2806
Last Price 0.0960
52-Week Low 0.0090

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar